ESTRO 2024 - Abstract Book

S2774

Interdisciplinary - Health economics & health services research

ESTRO 2024

The number of brachytherapy centres in a country indicated by responders ranged from 0 to 72, with two countries not providing the answer, fig. 2. Inconsistent responses were given in six countries, with ranges spanning from 7 to 34 within a single country. The accessibility of brachytherapy ranges from one brachytherapy centre per 0.44 mil. inhabitants to one per 2.5 mil. inhabitants, fig. 2. All countries perform brachytherapy for gynaecological cancer with prostate being the only other modality treated in more than ¾ of the countries, table I. Only one country reported gynaecological cancers being the only site treated with brachytherapy. Ten countries are treating more than eight different sites. As future brachytherapy indications, gynaecological and prostate cancer are indicated as most important sites by 94 % and 69 % of the responders, followed by skin, breast and salvage brachytherapy after recurrence, which all were indicated by >1/3 of the responders. Lowest scores were reported for lung and liver (<10%).

Ongoing phase II and III trials involving brachytherapy were reported by responders from 10 and 6 countries, respectively.

Table I: List of the number of countries reporting utilisation of brachytherapy for a given site. The ranges stem from deviating responses from some countries.

Sites

Number of countries performing brachytherapy

Gynae

26 (100%)

Prostate

20-23 (77-88%)

Skin

8-15 (31-58%)

Eye

8-14 (31-54%)

Head and Neck

7-14 (27-54%)

Salvage after recurrence

8-13 (31-50%)